Nasal dihexa delivery bypasses first-pass metabolism, achieving 5–7× higher bioavailability

Nasal dihexa bypasses first-pass metabolism but delivers 30-40% lower bioavailability

Dihexa nasal concentration ranges from 3–10 mg/ml, with 5 mg/ml

MOTS-C nasal spray delivers a mitochondrial peptide that supports metabolic

MOTS-C nasal spray delivers 40–60% bioavailability versus 95%+ with subcutaneous

MOTS-c nasal absorption delivers mitochondrial peptides directly to systemic circulation

MOTS-C nasal spray reconstitution requires precise bacteriostatic water ratios and

Dihexa nasal absorption bypasses first-pass metabolism, achieving faster CNS delivery

Nasal MOTS-c bypasses first-pass metabolism, delivering 40–60% more active peptide

MOTS-C nasal spray offers convenience but subcutaneous injection delivers 3–4×

NAD+ nasal spray delivers nicotinamide adenine dinucleotide directly to the

NAD+ nasal spray reaches peak plasma levels in 10–15 minutes

MOTS-c intranasal research shows 40–60% absorption efficiency via olfactory pathway.

NAD+ nasal spray reconstitution requires bacteriostatic water, refrigeration at 2–8°C,

NAD+ intranasal research reveals 30-40% bioavailability advantage over oral routes

NAD+ nasal concentration ranges from 50–200mg/mL depending on protocol goals.

NAD+ nasal sprays deliver 40–60% bioavailability through mucosal absorption, while

The retatrutide TRIUMPH 4 trial demonstrated 24.2% mean weight loss

NAD+ nasal absorption delivers nicotinamide adenine dinucleotide directly to the

Retatrutide delivers 24% weight loss versus Mounjaro’s 21% in trials.

Nasal NAD+ administration bypasses first-pass metabolism, achieving 40–60% bioavailability versus